Department of Cornea and Phacorefractive, The Eye Foundation, Coimbatore, Tamil Nadu, India.
Department of Cataract and Phacorefractive, The Eye Foundation, Coimbatore, Tamil Nadu, India.
Indian J Ophthalmol. 2021 Mar;69(3):559-562. doi: 10.4103/ijo.IJO_824_20.
To know the efficacy of the second donor conjunctival graft from the same site as that of the previous donor area in pterygium treatment.
Case record of patients were retrospectively analysed and those patients who had undergone pterygium excision previously, either for nasal or temporal pterygium excision and came with complaints of pterygium growth in opposite side of the bulbar conjunctiva in the same eye were included in the study. The patients with double head pterygium previously treated only over one side were also included. Total of 23 such patients were included in the study. The patients were followed up on post-operative day 1, 2 weeks, 6 weeks, 6 months and 1 year. The outcome measures like recurrence, graft edema, graft retraction, graft loss and other complications were noted in each follow up.
Among the 23 patients included in the study 9 were male and 14 were female patients with a mean age of 44±7.2 years (range 24-57 years). On an average follow up period of 15±8.5 months, only 1 patient among 23 patients had recurrence (4.43%). Other complications noted were graft retraction in 4 eyes (17.4%), sub conjunctival hemorrhage in 8 eyes (34.8%) and graft edema in 11 eyes (47.8%). Only one patient presented with granuloma (4.34%).
The second conjunctival graft from the same site is safe and effective with encouraging results in indicated cases.
了解同一部位的第二个供体结膜移植物在翼状胬肉治疗中的效果。
回顾性分析病例记录，纳入先前因鼻侧或颞侧翼状胬肉切除且同一眼球结膜对侧出现翼状胬肉生长的抱怨而接受手术的患者；先前仅对一侧进行过双头翼状胬肉治疗的患者也包括在内。共纳入 23 例符合条件的患者进行研究。患者在术后第 1、2 周、6 周、6 个月和 1 年进行随访。在每次随访中，均记录复发、移植物水肿、移植物回缩、移植物丢失和其他并发症等结局指标。
在纳入研究的 23 例患者中，男性 9 例，女性 14 例，平均年龄 44±7.2 岁（范围 24-57 岁）。在平均 15±8.5 个月的随访期间，23 例患者中仅 1 例复发（4.43%）。其他观察到的并发症包括 4 只眼的移植物回缩（17.4%）、8 只眼的结膜下出血（34.8%）和 11 只眼的移植物水肿（47.8%）。仅 1 例患者出现肉芽肿（4.34%）。
在适应证患者中，同一部位的第二个结膜移植物是安全有效的，结果令人鼓舞。
